GOTHENBURG, Sweden, April 17, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical AB (publ), Reg. No. 556759-8064 based in Gothenburg, to the Annual General Meeting on Wednesday, May 21, 2025. The information in the press release is intended for investors. The shareholders in Isofol Medical AB (publ), […]
GOTHENBURG, Sweden, April 11, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announced that the company’s annual report and corporate governance report for the financial year 2024 are now available, in Swedish as well as an English translation, on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors.
GOTHENBURG, Sweden, March 21, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the regulatory authority in Germany, BfArM, has given their final approval for the initiation of the new clinical trial of the company’s drug candidate arfolitixorin. The study will initially be conducted in Germany, where patient recruitment will commence shortly.
Isofol receives regulatory approval to initiate clinical study of arfolitixorin Read More »
GOTHENBURG, Sweden, February 19, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s year-end report for January – December 2024 is now available on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. CEO’s comment ” At the end of 2024, we received positive feedback
Isofol Medical AB (publ) publishes year-end report, January – December 2024 Read More »
GOTHENBURG, Sweden, November 19, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that the members of the nomination committee for the Annual General Meeting 2025 have been appointed in accordance with the principles for appointing nomination committees that were adopted at the Annual General Meeting 2024. The information
Isofol appoints nomination committee ahead of the Annual General Meeting 2025 Read More »
GOTHENBURG, Sweden, November 12, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–September 2024 is now available, in Swedish, on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. Third quarter, July–September 2024 Net revenue amounted to kSEK 0 (0) and
Isofol Medical AB (publ) publishes interim report, January–September 2024 Read More »
GOTHENBURG, Sweden, September 17, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces positive outcomes of a preliminary patentability report on a new international product patent application for arfolitixorin, submitted under the PCT (Patent Cooperation Treaty). If granted, the patent could significantly strengthen and prolong arfolitixorin’s intellectual property protection internationally. The information in
GOTHENBURG, Sweden, September 12, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that the company has terminated the liquidity guarantee agreement with Pareto Securities. The agreement expires on September 13, 2024. The information in the press release is intended for investors. The purpose of a liquidity guarantee agreement is to improve share
Isofol terminates liquidity guarantee agreement Read More »
GOTHENBURG, Sweden, August 21, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–June 2024 is now available, in Swedish, on the company’s website, www.isofolmedical.com. The information in the press release is intended for investors. Second quarter, April–June 2024 Net revenue amounted to kSEK 0 (0) and
Isofol Medical AB (publ) publishes interim report, January–June 2024 Read More »
GOTHENBURG, Sweden, July 30, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announced today that the company has appointed Margareta Hagman as the new Chief Financial Officer. She has extensive financial experience from biotech and pharmaceutical companies and will assume the position on August 13. The information in the press release is intended for
Isofol appoints Margareta Hagman as new Chief Financial Officer Read More »
